The MHRA has also granted approval to Faron Pharmaceuticals to conduct the BEXMAB trial of Clevegen in the UK.

The EMA’s CHMP has endorsed expanding the use of Palforzia to toddlers aged one to three years with peanut allergies.

Fate has announced the retirement of president and CEO Scott Wolchko with Bob Valamehr set to assume the role from 1 January ...

The research team at UQ has secured a grant of $344,000 from the National Foundation for Medical Research and Innovation.

CBC Group has completed the strategic acquisition of UCB's mature neurology and allergy business in China for $680m.

There is no excerpt because this is a protected post.